Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RV521 (sisunatovir) for RSV upper respiratory tract infection after hematopoietic cell transplantation
2019-003746-33Phase 2Terminated
- Sponsor
- ReViral
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing sisunatovir with placebo (2 arms). Primary endpoint: Progression to lower respiratory tract complication. Started May 2020; status: terminated.
02
Drugs
sisunatovir
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2019-003746-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003746-33.